MAPK14 and glioblastoma: These studies along with the results presented herein strongly suggest that targeting MAPK14 with MBZ or other pharmacological inhibitors represents a promising strategy to enhance chemotherapy efficacy in cancer, including temozolomide efficacy against GBM.